Business Context and Reporting Period
This Form 8-K is a current report filed by AgeX Therapeutics, Inc. (trading symbol: AGE) on December 30, 2021, covering events that occurred on December 29, 2021. The filing details the results of the company's 2021 annual meeting of stockholders. Note: The request metadata references "Serina Therapeutics, Inc.," but the filing text explicitly identifies the registrant as AgeX Therapeutics, Inc.
Key Financial Metrics
This filing is a corporate governance report and does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial-related data point disclosed is the authorization of additional shares for equity awards.
Material Changes and Voting Results
The filing reports the following material actions taken by stockholders at the annual meeting:
- Shareholder Participation: 29,963,317 shares (78.98% of voting power) were represented at the meeting out of 37,939,176 eligible shares.
- Election of Directors: Four directors were elected: Gregory H. Bailey, Joanne M. Hackett, Michael H. May, and Michael D. West. Michael D. West received the highest number of votes for (23,704,422), while the others received approximately 19.7 to 19.9 million votes for.
- Accountant Ratification: Stockholders ratified the appointment of WithumSmith+Brown, PC as the independent registered public accountants for the 2021 fiscal year.
- Equity Plan Amendment: Stockholders approved an amendment to the 2017 Equity Incentive Plan to make an additional 500,000 shares of common stock available for equity awards.
Guidance, Outlook, and Risks
The filing contains standard forward-looking statement disclaimers, noting that actual results may differ materially from anticipated results due to risk factors detailed in other periodic reports. No specific financial guidance, operational outlook, or new risk contingencies were disclosed in this document.
Investor Verification Checklist
- Verify the impact of the 500,000 share increase on the 2017 Equity Incentive Plan on future dilution.
- Review the "Risk Factors" section in the company's most recent 10-K or 10-Q for details on the forward-looking statements mentioned in this filing.
- Confirm the tenure and specific roles of the newly elected directors (Bailey, Hackett, May, West) in subsequent governance filings.
- Note the significant number of broker non-votes (5,699,975) on the director election and equity plan amendment, indicating a portion of shares held in street name did not receive voting instructions.